Treatment of immune thrombocytopenia with intravenous immunoglobulin and insights for other diseases: A historical review

Swiss Medical Weekly

Volumn 142, Issue MAY, 2012, Pages

  Imbach, Paul ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Historical review; Immune thrombocytopenia; Intravenous immuneglobuline

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; FAS ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G; VINCRISTINE; IMMUNOGLOBULIN;

AGAMMAGLOBULINEMIA; ALZHEIMER DISEASE; ANTIGEN ANTIBODY COMPLEX; APLASTIC ANEMIA; APOPTOSIS; ASEPTIC MENINGITIS; ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; B LYMPHOCYTE; CELL ACTIVATION; CHICKENPOX; CHILL; CHRONIC DISEASE; CHRONIC FATIGUE SYNDROME; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CYTOKINE RELEASE; DENDRITIC CELL; DERMATOMYOSITIS; DRUG MECHANISM; DRUG PURIFICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; ENCEPHALITIS; EPIDERMOLYSIS; FEVER; GRAVES DISEASE; GUILLAIN BARRE SYNDROME; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INCLUSION BODY MYOSITIS; INFECTION; INFLAMMATORY DISEASE; LIVER DISEASE; LYMPHOCYTOPENIA; MOTOR NEUROPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; MYALGIA; MYASTHENIA GRAVIS; NAUSEA; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NEUTROPENIA; PEMPHIGUS; POLYMYOSITIS; PURPURA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR DOWN REGULATION; RECURRENT DISEASE; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; SPONTANEOUS ABORTION; STEVENS JOHNSON SYNDROME; STIFF MAN SYNDROME; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; URTICARIA; UVEITIS; WISKOTT ALDRICH SYNDROME; HISTORY; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGY;

AUTOIMMUNE DISEASES; HISTORY, 20TH CENTURY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 84863441201     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2012.13593     Document Type: Review

References (66)

1. Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP. High-dose intravenous immunoglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediat Acta. 1981;46:81-6. (Pubitemid 11137811)
2. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228-31.
3. Imbach P, Wagner HP, Berchtold W, Gaedicke G, Hirt A, Joller P, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet. 1985;2:464-8.
4. Gugler E. Die kindlichen Thrombopenien. In: Rossi E, ed. Päd Fortbildungskurse. Basel, Switzerland: Karger, 1964;11-12:143-58.
5. Barandun S, Imbach P, Morell A, Wagner HP. Traitement du purpura thrombocytopénique par des immunoglobulines. Méd et Hyg. 1982;40:1774-8. (Pubitemid 13211969)
6. Fehr J, Hofman V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med. 1982;306:1254-8. (Pubitemid 12100206)
7. Newland AC, Treleaven JG, Minchinton RM, Waters AH. High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet. 1983;1(8316):84-7. (Pubitemid 13222137)
8. Bussel JB, Hilgartner M. The use of and mechanism of action of high dose intravenous immunoglobulin in the treatment of immune haematologic disease. Br J Haematol. 1984;56:l-7.
9. Cohn EJ, Strong LE, Hughes WL, et al. Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946;68:459-75.
10. Oncley JL, Melin M, et al. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma. J Am Chem Soc. 1949;71(2):541-50.
11. Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human gamma-globulin. Vox Sang. 1962;7:157-74.
12. Hooper JA. Intravenous immunoglobulins: evolution of commercial IVIG preparations. Immunol Allergy Clin North Am. 2008;28:765-78.
13. Haessig A. 50 Jahre Blutspendedienst des Schweizerischen Roten Kreuzes. Schweiz Med Wochenschrift. 1991;121:156.
14. Kistler P, Friedli H. Ethanol precipitation. In: Curling JM, ed. Methods of plasma protein fractionation. London: Academic Press 1980;3-16.
15. Kistler P, Nitschmann H. Large scale production of human plasma fractions. Eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang. 1962;7:414-24.
16. Seite JF, Shoenfeld Y, Youninou P, Hillion S. What is the contents of the magic draft IVIg? Autoimmun Rev. 2008;7:435-9.
17. Sorensen R. Expert opinion regarding clinical and other outcome considerations in the formulary review of immune globulin. J Manag Care Pharm. 2007;13:278-83. (Pubitemid 46730897)
18. Carbone J. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf. 2007;2:9-18. (Pubitemid 46723165)
19. Schleis TG. The process: new methods of purification and viral safety. Pharmacotherapy. 2005;25(11 pt 2):73S-77S. (Pubitemid 41566907)
20. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med. 1994;331:1607-11. (Pubitemid 24372058)
21. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol. 2008;122:1238-39.
22. Ryan ME, Webster ML, Statler JD. Adverse effects of intravenous immunoglobulin therapy. Clin Pediatr. (Phila) 1996;35:23-31. (Pubitemid 26026379)
23. Caress JB, Cartwright MS, Donofrio PD, Peacock JE Jr. The clinical features of 16 cases of stroke associated with administration of IVIg. Neurology. 2003;60:1822-4. (Pubitemid 36737082)
24. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223-6. (Pubitemid 24070955)
25. Imbach P, Lazarus A, Kühne T. Intravenous immunoglobulins induce potentially synergistic immunomodulations in autoimmune disorders. Vox Sanguinis. 2010;98:385-94.
26. Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, Kazatchkine MD, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27:233-45. (Pubitemid 46790823)
27. Debré M, Bonnet MC, Fridman WH, Carosella E, Philippe N, Reinert P, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet. 1993;342(8877):945-9. (Pubitemid 23305497)
28. Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity. 2007;26(1):67-78. (Pubitemid 46127754)
29. Samuelsson A, Towers T, Ravetch J. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484-6. (Pubitemid 32097072)
30. Chang J, Shi PA, Chiang EY, Frenette PS. Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood. 2008;111:915-23.
31. Gianella-Borradori A, Hirt A, Lüthy A, Wagner HP, Imbach P. Haemophilia due to factor VIII inhibitors in a patient suffering from an autoimmune disease. Treatment with intravenous immunoglobulin. A case report. Blut. 1984;48:403-7. (Pubitemid 14094307)
32. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Antiidiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 1984;2(8406):765-8. (Pubitemid 14007575)
33. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol. 1989;143:4104-9. (Pubitemid 20012601)
34. Berchtold P, Date GL, Tani P, McMillan R. Inhibition of autoantibody binding to platelet glycoprotein Iib / IIIa by anti-idiotype antibodies in intravenous gammaglobulin. Blood. 1989;74:2414-7. (Pubitemid 19286460)
35. Kondo N, Ozawa T, Mushiake K, Motoyoshi F, Kameyama T, Kasahara K, et al. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol. 1991;11:152-8.
36. Le Pottier L, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO. Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci. 2007;1110:426-32. (Pubitemid 350043031)
37. Semple JW, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood. 1991;78(10):2619-25.
38. Semple JW, Bruce S, Freedman J. Suppressed natural killer cell activity in patients with chronic autoimmune thrombocytopenic purpura. Am J Hematol. 1991;37(4):258-62.
39. Semple JW, Milev Y, Cosgrave D, Mody M, Hornstein A, Blanchette V, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura; relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996;87:4245-54. (Pubitemid 26152268)
40. Kessel A, Ammuri H, Peri R, Pavlotzky ER, Blank M, Shoenfeld Y, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol. 2007;179:5571-5.
41. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111:715-22.
42. Teeling JL, Jansen-Hendriks T, Kuijpers TW, de Haas M, van de Winkel JG, Hack CE, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimmers: studies in experimental immune thrombocytopenia. Blood. 2001;98:1095-9.
43. Siragam V, Brine D, Crow AR, Song S, Freedman J, Lazarus AH. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest. 2005;115:155-60. (Pubitemid 40385516)
44. Siragam V, Crow AR, Brine D, Song S, Freedman J, Lazarus AH. Intravenous immunoglobulin ameliorates ITP via activating Fcgamma receptors on dendritic cells. Nat Med. 2006;12:688-92. (Pubitemid 43865239)
45. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 2003;101:758-65. (Pubitemid 36077604)
46. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513-33. Review. (Pubitemid 351600384)
47. Hansen RJ, Balthasar JP. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb Haemost. 2002;88:898-9. (Pubitemid 36018773)
48. Li N, Zhao M, Hilario-Vargas J, Prisayanh P, Warren S, Diaz LA, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering disease. J Clin Invest. 2005;115:3440-50. (Pubitemid 43121832)
49. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276(9):6591-604.
50. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313(5787):670-3. (Pubitemid 44201145)
51. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011;475(7354):110-3.
52. Lutz HU, Stammler P, Bianchi V, Trüeb RM, Hunziker T, Burger R, et al. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood. 2004;103:465-72. (Pubitemid 38140074)
53. Basta M, Van Goor F, Luccioli S, Billings EM, Vortmeyer AO, Baranyi L, et al, Metcalfe DD. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med. 2003;9:431-48.
54. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010;47(13):2170-5.
55. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-3. (Pubitemid 28483679)
56. Lemieux R, Bazin R, Ne'ron S. Therapeutic intravenous immunoglobulins. Mol Immunol. 2005;42:839-48. Review. (Pubitemid 40489033)
57. Hartung HP. Advances in the understanding of the mechanism of action of IVIg. J Neurol. 2008;255(Suppl 3):3-6. Review.
58. Dalakas, et al. Clinical Use of IVIG in Neurology in: Immunoglobulin Therapy. A.H. Lazarus, J.W. Semple eds. 2010, AABB Press. Pages 80-95.
59. Jolles S, Hughes J. Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema. Int Immunopharmacol. 2006;6:579-91. Review.
60. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3-40. Review. (Pubitemid 26230668)
61. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-86. Epub 2009 Oct 21. Review.
62. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-207.
63. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-93.
64. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103(4):1364-9. (Pubitemid 38168649)
65. Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011;365(8):734-41.
66. Kuhne T, Berchtold W, Michaels LA, Wu R, Donato H, Espina B, et al. Newly diagnosed immune thrombocytopenia in children and adults, a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica. 2011;96(12):1831-7.